Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PNP | P00491 | 2/20 | 0.45 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | TK1 | P04183 | 1/20 | 0.41 |
| ▸ | HINT1 | P49773 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216535 | 1.00 | ADORA3 (0.52) | ADORA3POLBPNPHPRT1STING1 | |
| SCHEMBL26136545 | 1.00 | ADORA3 (0.52) | ADORA3POLBPNPHPRT1STING1 | |
| SCHEMBL26135607 | 1.00 | ADORA3 (0.52) | ADORA3POLBPNPHPRT1STING1 | |
| SCHEMBL31652885 | 1.00 | ADORA3 (0.52) | ADORA3POLBPNPHPRT1STING1 | |
| SCHEMBL9548716 | 0.91 | ADORA3 (0.53) | ADORA3POLBPNPHPRT1STING1 | |
| SCHEMBL9548710 | 0.91 | ADORA3 (0.53) | ADORA3POLBPNPHPRT1STING1 | |
| SCHEMBL7211702 | 0.85 | ALDH1A1 (0.53) | ADORA3HPRT1STING1 | |
| SCHEMBL9548662 | 0.84 | ADORA3 (0.56) | ADORA3POLBPNPHPRT1STING1 | |
| SCHEMBL9548656 | 0.84 | ADORA3 (0.56) | ADORA3POLBPNPHPRT1STING1 | |
| SCHEMBL26272165 | 0.84 | ADORA3 (0.56) | ADORA3POLBPNPHPRT1STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1177202-B1 | 4'-C-ETHYNYL PURINE NUCLEOSIDES | YAMASA CORP (JP) | 2003-09-24 | — | — | EP | claimed |
| US-6333315-B1 | FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-12-25 | — | — | US | claimed |
| US-20260035403-A1 | NUCLEOSIDE LINE-1 INHIBITORS | TRANSPOSON THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| CN-119278043-A | Nucleoside LINE-1 inhibitors | 转位治疗股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2023192505-A2 | METHOD FOR TREATING CANCER WITH A DNA DAMAGE REPAIR ENZYME INHIBITOR | PRIMEFOUR THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192491-A2 | NUCLEOSIDE LINE-1 INHIBITORS | TRANSPOSON THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | PRIMEFOUR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | PRIMEFOUR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-1177202-B1 | 4'-C-ETHYNYL PURINE NUCLEOSIDES | YAMASA CORP (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-6403568-B1 | FOR THERAPY OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) | YAMASA CORPORATION (JP) | 2002-06-11 | — | — | US | disclosed |
| US-20020022722-A1 | 4'-C-ethynyl pyrimidine nucleoside compounds | OHRUI HIROSHI (JP) | 2002-02-21 | — | — | US | disclosed |
| EP-1177201-A1 | 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2002-02-06 | — | — | EP | disclosed |
| US-6333315-B1 | FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-12-25 | — | — | US | disclosed |
| US-6291670-B1 | VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| WO-2000069876-A1 | 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022722-A1 | 4'-C-ethynyl pyrimidine nucleoside compounds | PNP, TYMP, NUDT1 | ADORA3 40/4885POLB 143/4885PNP 1/4885 |
| US-20260035403-A1 | NUCLEOSIDE LINE-1 INHIBITORS | L3MBTL1, TDP1, TRDMT1 | ADORA3 1252/4885POLB 171/4885PNP 56/4885 |
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | TYMP, TYMS, DCTD | ADORA3 732/4885POLB 59/4885PNP 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.